drugset
drugset / Trial / NCT06518551

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

NCT06518551 ↗

Phase 1/2 Recruiting 49 enrolled Omar Nadeem, MD Bristol-Myers Squibb · collabCelgene Corporation · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)

Timeline

Start
2024-11-01
Primary completion
2029-12-31
Completion
2034-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Elotuzumab Monoclonal antibody 300 mg Intravenous
Subject Elotuzumab Monoclonal antibody 400 mg Intravenous
Subject Iberdomide Small molecule 0.15 mg Oral
Subject Iberdomide Small molecule 0.2 mg Oral
Subject Iberdomide Small molecule 0.3 mg Oral
Subject Iberdomide Small molecule 0.45 mg Oral
Subject Iberdomide Small molecule 0.6 mg Oral
Subject Iberdomide Small molecule 0.75 mg Oral
Background Dexamethasone Small molecule 2 mg Oral
Background Dexamethasone Small molecule 4 mg Oral

Indications

plasma cell myeloma